No Data
The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
Due to the decrease in sales volume of H1's main products, Chongqing Zhifei Biological Products reported a decrease in revenue and net income in its semi-annual report. The volume of Merck's quadrivalent HPV vaccine, which the company represents, decreased by more than 90% compared to the previous year. With the accelerated development of domestically-produced nine-valent HPV vaccines, the company's pressure will further increase.
The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.
Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.
Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports
①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.
Shenzhen Salubris Pharmaceuticals' H1 revenue increased by 20%, but net profit growth is under pressure. The launch of two new drugs is facing regulatory negotiations.
① In the first half of this year, shenzhen salubris pharmaceuticals' revenue grew by more than 20%, but net profit attributable to shareholders only increased by less than 2%; ② During the reporting period, shenzhen salubris pharmaceuticals had two innovative products approved for listing, both of which have passed the initial review by the national discussion this year; ③ shenzhen salubris pharmaceuticals has four new drugs undergoing market approval, including three chemical drugs and one biological drug.
Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations
①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.
How promising is the vitamins bull market? Zhejiang Nhu's Q2 net profit of 1.335 billion yuan reached a new high|Interpretation of financial report.
① Vitamins have significantly boosted manufacturers' performance in the bull market; ② Q2 net profit of Zhejiang Nhu reached a new high compared to the same period in history; ③ The company benefits from a high proportion of overseas business; ④ The Q3 increase has widened, further benefiting manufacturers.